文献速递心脑血管急症

替格瑞洛联合阿司匹林1个月后替格瑞洛单药治疗23个月对比标准双联抗血小板治疗12个月后阿司匹林单药治疗12个月:药物洗脱支架植入后的多中心、开放标签、随机优效性试验

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
PubMed 文献 · Lancet · 2018-08-27
一句话结论GLOBAL LEADERS试验显示,替格瑞洛联合阿司匹林1个月后替格瑞洛单药治疗23个月,在2年全因死亡或新发Q波心肌梗死复合终点上未优于标准双联抗血小板治疗12个月后阿司匹林单药治疗12个月。

GLOBAL LEADERS是在18个国家130个中心进行的随机、开放标签、优效性试验,纳入15 968例接受biolimus A9洗脱支架经皮冠状动脉介入治疗(PCI)的稳定性冠心病或急性冠脉综合征患者。患者随机接受试验组方案(阿司匹林75-100 mg每日一次联合替格瑞洛90 mg每日两次共1个月,随后替格瑞洛单药治疗23个月)或对照组方案(标准双联抗血小板治疗12个月:稳定性冠心病用阿司匹林75-100 mg每日一次联合氯吡格雷75 mg每日一次,急性冠脉综合征用阿司匹林75-100 mg每日一次联合替格瑞洛90 mg每日两次,随后阿司匹林单药治疗12个月)。2年时主要终点(全因死亡或经中心盲法判定的非致命性新发Q波心肌梗死复合终点)在试验组发生304例(3.81%),对照组349例(4.37%),率比0.87(95%CI 0.75-1.01;p=0.073),未达统计学显著。关键次要安全终点BARC 3级或5级出血在试验组163例(2.04%),对照组169例(2.12%),率比0.97(95%CI 0.78-1.20;p=0.77)。作者结论认为试验组方案在2年主要终点上未优于标准方案。

要点

  • GLOBAL LEADERS纳入15 968例接受biolimus A9洗脱支架PCI的稳定性冠心病或急性冠脉综合征患者,随机1:1分配至试验组或对照组。
  • 2年主要终点(全因死亡或非致命性新发Q波心肌梗死)试验组3.81% vs 对照组4.37%,率比0.87(95%CI 0.75-1.01;p=0.073),未达统计学显著。
  • BARC 3级或5级出血试验组2.04% vs 对照组2.12%,率比0.97(95%CI 0.78-1.20;p=0.77),两组无显著差异。
  • 急性冠脉综合征与稳定性冠心病预设亚组间主要终点治疗效果无显著异质性(p=0.93)。
  • 作者结论:替格瑞洛联合阿司匹林1个月后替格瑞洛单药治疗23个月,在PCI后2年预防全因死亡或新发Q波心肌梗死方面未优于标准双联抗血小板治疗12个月后阿司匹林单药治疗12个月。

适用人群与场景

  • 接受经皮冠状动脉介入治疗并植入biolimus A9洗脱支架的稳定性冠心病或急性冠脉综合征患者。
  • 试验在18个国家130个中心进行,随机分组按中心和临床表现(稳定性冠心病 vs 急性冠脉综合征)分层。

处置流程与药物剂量

  • 试验组:阿司匹林75-100 mg每日一次联合替格瑞洛90 mg每日两次,共1个月;随后替格瑞洛单药治疗23个月。
  • 对照组:标准双联抗血小板治疗12个月——稳定性冠心病患者用阿司匹林75-100 mg每日一次联合氯吡格雷75 mg每日一次;急性冠脉综合征患者用阿司匹林75-100 mg每日一次联合替格瑞洛90 mg每日两次;随后阿司匹林单药治疗12个月。

研究设计与关键结果

  • GLOBAL LEADERS为随机、开放标签、优效性试验,在18个国家130个中心进行,纳入15 968例接受biolimus A9洗脱支架PCI的稳定性冠心病或急性冠脉综合征患者,随机1:1分配至试验组(7980例)或对照组(7988例)。
  • 2年主要终点(全因死亡或经中心盲法判定的非致命性新发Q波心肌梗死复合终点):试验组304例(3.81%)vs 对照组349例(4.37%),率比0.87(95%CI 0.75-1.01;p=0.073)。
  • 关键次要安全终点BARC 3级或5级出血:试验组163例(2.04%)vs 对照组169例(2.12%),率比0.97(95%CI 0.78-1.20;p=0.77)。
  • 预设亚组(急性冠脉综合征 vs 稳定性冠心病)间主要终点治疗效果无显著异质性(p=0.93)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机优效性试验(GLOBAL LEADERS,ClinicalTrials.gov NCT01813435)。
  • 作者结论:替格瑞洛联合阿司匹林1个月后替格瑞洛单药治疗23个月,在PCI后2年预防全因死亡或新发Q波心肌梗死方面未优于标准双联抗血小板治疗12个月后阿司匹林单药治疗12个月。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于接受biolimus A9洗脱支架PCI的稳定性冠心病或急性冠脉综合征患者,替格瑞洛联合阿司匹林1个月后替格瑞洛单药治疗23个月的方案,在2年全因死亡或新发Q波心肌梗死复合终点上未优于标准双联抗血小板治疗12个月后阿司匹林单药治疗12个月(率比0.87,95%CI 0.75-1.01;p=0.073)。
  • 两组BARC 3级或5级出血发生率无显著差异(2.04% vs 2.12%;率比0.97,95%CI 0.78-1.20;p=0.77)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.

METHODS: GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months. Randomisation was concealed, stratified by centre and clinical presentation (stable coronary artery disease vs acute coronary syndrome), and blocked, with randomly varied block sizes of two and four. The primary endpoint at 2 years was a composite of all-cause mortality or non-fatal centrally adjudicated new Q-wave myocardial infarction as assessed by a core lab in a blinded manner. The key secondary safety endpoint was site-reported bleeding assessed according to the Bleeding Academic Research Consortium criteria (grade 3 or 5). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01813435, and is closed to new participants, with follow-up completed.

FINDINGS: Between July 1, 2013, and Nov 9, 2015, 15 968 participants were randomly assigned, 7980 to the experimental group and 7988 to the control group. At 2 years, 304 (3·81%) participants in the experimental group had died or had a non-fatal centrally adjudicated new Q-wave myocardial infarction, compared with 349 (4·37%) participants in the control group (rate ratio 0·87 [95% CI 0·75-1·01]; p=0·073]). There was no evidence for a difference in treatment effects for the primary endpoint across prespecified subgroups of acute coronary syndromes and stable coronary artery disease (p=0·93). Grade 3 or 5 bleeding occurred in 163 participants in the experimental group and 169 in the control group (2·04% vs 2·12%; rate ratio 0·97 [95% CI 0·78-1·20]; p=0·77).

INTERPRETATION: Ticagrelor in combination with aspirin for 1 month followed by ticagrelor alone for 23 months was not superior to 12 months of standard dual antiplatelet therapy followed by 12 months of aspirin alone in the prevention of all-cause mortality or new Q-wave myocardial infarction 2 years after percutaneous coronary intervention.

FUNDING: AstraZeneca, Biosensors, and The Medicines Company.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018. PMID: 30166073. doi:10.1016/S0140-6736(18)31858-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。